Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03712202 · ClinicalTrials.gov registry record · Phase 2

Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

A Phase 2 study of Classic Hodgkin Lymphoma and Ann Arbor Stage IIB Hodgkin Lymphoma, sponsored by City of Hope Medical Center.

Active
Registry status
Phase 2
Development phase
155
Enrollment target
17
Study locations

NCT03712202 is a Phase 2 study of Classic Hodgkin Lymphoma and Ann Arbor Stage IIB Hodgkin Lymphoma that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 155 participants, below the 235-participant average among 9 other Classic Hodgkin Lymphoma trials with a reported enrollment target (34% lower). The trial reports 17 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03712202, a Phase 2 study of Classic Hodgkin Lymphoma and Ann Arbor Stage IIB Hodgkin Lymphoma, is active but no longer recruiting, sponsored by City of Hope Medical Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
155 participants
Enrollment target
17
Study locations

Study Summary

This phase II trial studies how well brentuximab vedotin and nivolumab work in treating patients with stage I-II classic Hodgkin lymphoma. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Conditions Studied

Classic Hodgkin Lymphoma Ann Arbor Stage IIB Hodgkin Lymphoma Ann Arbor Stage IB Hodgkin Lymphoma Ann Arbor Stage II Hodgkin Lymphoma Ann Arbor Stage IIA Hodgkin Lymphoma Ann Arbor Stage I Hodgkin Lymphoma Ann Arbor Stage IA Hodgkin Lymphoma Lymphocyte-Rich Classic Hodgkin Lymphoma Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma

Interventions

  • DRUG Doxorubicin
  • BIOLOGICAL Nivolumab
  • DRUG Brentuximab Vedotin
  • DRUG Dacarbazine
  • DRUG Bleomycin

Study Locations (17)

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston
  • Dana-Farber Cancer Institute - Boston
  • Massachusetts General Hospital - Charlestown

California

  • City of Hope Medical Center - Duarte
  • University of California San Diego - San Diego

Illinois

  • Northwestern University - Chicago
  • University of Chicago Comprehensive Cancer Center - Chicago

Ohio

  • Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center - Cleveland
  • Ohio State University Comprehensive Cancer Center - Columbus

Alabama

  • University of Alabama at Birmingham Cancer Center - Birmingham

Georgia

  • Emory University Hospital/Winship Cancer Institute - Atlanta

New Jersey

  • Hackensack University Medical Center - Hackensack

New York

  • NYP/Weill Cornell Medical Center - New York

Trial Details

FieldValue
Enrollment Target 155 participants
Start Date 2018-11-28
Est. Completion 2024-12-23
Phase Phase 2

Sponsor

City of Hope Medical Center

582 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03712202

The ClinicalTrials.gov registry entry for NCT03712202 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 235-participant average among 9 other Classic Hodgkin Lymphoma trials with a reported enrollment target (34% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Classic Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Doxorubicin is the first listed.

NCT03712202 reports 17 study locations spanning 12 distinct geographic areas - top geographies include Massachusetts, California, Illinois.

Frequently Asked Questions

What is clinical trial NCT03712202 about?

NCT03712202 is a clinical study titled "Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma". This phase II trial studies how well brentuximab vedotin and nivolumab work in treating patients with stage I-II classic Hodgkin lymphoma. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a target...

What is the current status of trial NCT03712202?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2018-11-28. Estimated completion is 2024-12-23.

What conditions does trial NCT03712202 study?

This clinical trial studies the following conditions: Classic Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma.

What interventions are being tested in trial NCT03712202?

The interventions under investigation include: Doxorubicin (DRUG), Nivolumab (BIOLOGICAL), Brentuximab Vedotin (DRUG), Dacarbazine (DRUG), Bleomycin (DRUG).

Who is sponsoring clinical trial NCT03712202?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03712202 being conducted?

This trial has 17 study locations across Alabama, California, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Classic Hodgkin Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Classic Hodgkin Lymphoma

All registered trials for this condition

Ann Arbor Stage IIB Hodgkin Lymphoma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.